Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.516 -0.104 (-1.57%)
Streaming Delayed Price Updated: 3:22 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
39 40 Next >
Psychedelic Stock Gainers And Losers From March 28, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From March 27, 2023
Via Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 22, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From March 21, 2023
Via Benzinga
Cybin Inc. Was Down 70% In 2022 But Has Bounced Back By 59% YTD - Here's Why
A review of Cybin Inc.'s latest quarterly financials, the history of its stock price performance, and the price forecasts for the stock over the next 12 months. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From March 20, 2023
Via Benzinga
The "Multi-Bagger" Portfolio: An Update
Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 - DOWN 73% vs. 2021 - but perhaps some of them will bounce back with major - dare I say 
Via Talk Markets
Psychedelic Stock Gainers And Losers From March 17, 2023
Via Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll... 
Via Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 9, 2023
Via Benzinga
Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate at Oppenheimer 33rd Annual Health Care Conference
Via Investor Brand Network
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From Cybin Inc.
Via Business Wire
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 6, 2023
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder, Other Experts in Psychedelics Discussions
Via Investor Brand Network
Cybin: Positive Clinical Trial On Psilocybin Analog For Major Depression & Updates On DMT Analog Program
Psychedelics biotech company Cybin Inc. 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 2, 2023
Via Benzinga
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
From Cybin Inc.
Via Business Wire
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From February 28, 2023
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.